FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.
ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia(pamidronate disodium for injection) for the treatment of patientswith osteolytic bone metastases of breast cancer, in conjunctionwith standard antineoplastic therapy.
The drug has been on the market since 1991 and is also indicatedfor the treatment of osteolytic bone lesions of multiple myeloma,moderate-to-severe hypercalcemia of malignancy, and moderate-to-severePaget's disease.
Articles in this issue
AgeAwareness Group Urges the Media to Keep Breast Cancer Issues on the Public Agenda
Multimodality Approaches Used in Esophageal Cancer
Talking With Your Doctor About Cancer and Its Therapy
Guttman Institute Reopens With Expanded Screening Services
Weight Gain, Not Fat Intake, Increases Breast Cancer Risk
Knowing When to Bow Out Gracefully
Chemo Appears Not To Raise Birth Defect Risk in Offspring
Discovery of HIV-1 Protein Structure Could Lead to New Therapies
'Friends of Cancer Research' Will Lead New Public Education Campaign
Cost of the New HIV Therapies Creates a Doctor's Dilemma
FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
Advance Directives Registry Offers Instant Access
Gene Mutation Provides Resistance to HIV Infection
Jury Decision Rattles Tobacco Company Stock Prices
Community Activities Help Some Smokers Quit
Recent Videos
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
T-DXd Benefit May Extend to Earlier Settings and HER2-Low Breast Cancers
Acalabrutinib/Chemotherapy Poised to Be Effective in High-Risk MCL
Tirzepatide May Increase AEs in HR+/HER2– Breast Cancer Treatment
Bolstering Access to Breast Cancer Screening for Genome Markers
Elacestrant Combos Can Open New Pathways in ESR1 Breast Cancer Treatment
Elacestrant’s Real World Outcomes Improve Over Clinical Findings in Breast Cancer
Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer
Related Content
